Skip to main
BMEA

BMEA Stock Forecast & Price Target

BMEA Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 57%
Buy 29%
Hold 14%
Sell 0%
Strong Sell 0%

Bulls say

Biomea Fusion Inc. is demonstrating a positive outlook due to significant advancements in its clinical programs, particularly the promising results of icovamenib's Phase II trial and the initiation of BMF-650's Phase I trial, indicating strong potential for diabetes and obesity treatment. Financially, the company has shown improvement with a reduced net loss of $16.4 million in Q3 2025 compared to $32.8 million in Q3 2024, alongside a more than 50% decline in operating expenses year-over-year. Moreover, the favorable pharmacokinetic profile and safety findings further bolster investor confidence in the company's pipeline as it prepares for upcoming trials.

Bears say

Biomea Fusion Inc. has reported a significant decrease in research and development (R&D) expenses, dropping from $27.2 million in Q3 2024 to $14.4 million in Q3 2025, which may raise concerns regarding the company's investment in its drug pipeline. General and administrative (G&A) expenses also saw a decline from $6.8 million to $4.2 million, suggesting potential cost-cutting measures that could impact operational capabilities. Furthermore, the reduction in the price target from $16.00 to $12.00 indicates a reevaluation of the company's growth prospects and overall market confidence.

BMEA has been analyzed by 7 analysts, with a consensus rating of Buy. 57% of analysts recommend a Strong Buy, 29% recommend Buy, 14% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Biomea Fusion Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Biomea Fusion Inc (BMEA) Forecast

Analysts have given BMEA a Buy based on their latest research and market trends.

According to 7 analysts, BMEA has a Buy consensus rating as of Feb 14, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8.71, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8.71, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Biomea Fusion Inc (BMEA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.